Uniphar stock
Price history
+14.63% over the period1 year: from €3.76 (November 17, 2025) to €4.31 (November 16, 2026), +14.63%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €4.31 |
| October 30, 2026 | €3.98 |
| September 30, 2026 | €4.06 |
| August 31, 2026 | €4.24 |
| July 31, 2026 | €4.25 |
| June 30, 2026 | €4.45 |
| May 29, 2026 | €4.56 |
| April 30, 2026 | €4.16 |
| March 31, 2026 | €3.80 |
| February 27, 2026 | €4.09 |
| January 30, 2026 | €3.83 |
| December 31, 2025 | €3.52 |
| November 28, 2025 | €3.77 |
| November 17, 2025 | €3.76 |
At a glance
The company
Diversified healthcare services company providing pharmaceutical and medical device distribution, pharmacy operations, and related support services across Ireland, UK, Netherlands and internationally
Latest results
Quarter to June 30, 2026 · EPS €0.04
Next event
TickerLandia's take on Uniphar
- Pricier than usual relative to earnings: P/E on the latest fiscal year 22 vs a median of 18 over its last 7 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 21 vs 28 (−24%) in a group of 11.
- Strong point: Earnings stability (66/100 in its group). Weak point: Dividend (24/100).
- “Most upside for analysts” (Ireland): No. 2 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−13.37% from the 52-week high
Analysts · 8 analysts
Average target€5.57+29.21% vs. price
Buy 8 · Hold 0 · Sell 0
TickerLandia Fingerprint: Uniphar
Compared with similar companies: low dividend, low financial strength, and high earnings stability.
Financials and price compared with 11 companies in the medical distribution industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage40
How much it costs relative to what it produces.
Metric Value Position in group Price/book 2.61 28 Price/sales 0.35 50 P/E (trailing 12 months) 21.4 32 Forward P/E 15.3 41 EV/EBITDA 14.2 50 Profitabilityaverage49
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 2.9% 41 Gross margin 14.9% 59 Net margin 1.7% 50 ROE 13.4% 65 ROA 3.6% 32 Earnings stabilityhigh66
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.2% 77 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 55 Growthhigh62
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +14.09% 86 Revenue growth (year over year) +7.20% 59 Earnings growth (year over year) +16.70% 41 Financial strengthlow30
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 1.22 15 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.06 32 Current ratio 0.97 50 Interest coverage 4.49 23 Dividendlow24
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 10.3% 15 Consecutive dividend years at least 7 years 41 Dividend yield 0.5% 15 Market momentumaverage47
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +9.87% 49 Distance from 200-day average +1.72% 45 Risklow38
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 22.0% 41 Volatility (60 days) 23.2% 34
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Uniphar is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Uniphar's P/E today is 22.1, above the median of its last 7 fiscal years (18.1; between 9.02 and 28.1 from 2019 to 2025). Uniphar's P/E (trailing 12 months): 21.4, −24% against the median of a group of 11 similar companies (28.2).
Compared with 11 similar companies
| Metric | Uniphar | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 21.4 | Middle | |
| Forward P/E | 15.3 | Middle | |
| Operating margin | 2.9% | Middle | |
| ROE | 13.4% | Middle | |
| Debt/equity | 1.22 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Uniphar. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€1.59B
Latest quarter · Q2 2026
Net income
€19.99M
Latest quarter · Q2 2026
Quarterly net margin
1.3%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €1.11B
- P/E
- 21.4
- EPS
- €0.20
- Volume
- 515.14K
- Daily trading
- €1.23M
- Dividend yield
- 0.48%
- Last ex-dividend on September 17, 2026
How Uniphar is changing
All resultsRevenue grew 11.0% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 100% of net income
Revenue has grown for 8 fiscal years in a row
Returns
Uniphar returns with dividends
€1,000 invested in Uniphar 5 years ago, on November 16, 2021, would be worth €1,007 today with dividends reinvested: +0.67% in total, +0.13% per year. On price alone it would be €977 (−2.27%).
| Period | Uniphar | €1,000 becomes |
|---|---|---|
| 1 month | +7.75% | €1,078 |
| 6 months | −0.23% | €998 |
| Year to date | +22.44% | €1,224 |
| 1 year | +15.21% | €1,152 |
| 3 years | +110.53% | €2,105 |
| 5 years | +0.67% | €1,007 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Uniphar: technical analysis
Uniphar shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 13.8% below its all-time closing high (€5.00, December 31, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +2.26%
Support and resistance
Price areas where Uniphar has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€4.42+2.44%2 touches, last on November 5, 2026
- Resistance€4.35+0.90%5 touches, last on September 8, 2026
- Last price€4.31
- Support€4.18−2.98%3 touches, last on September 30, 2026
- Support€4.12−4.45%6 touches, last on October 15, 2026
- Support€3.88−9.92%6 touches, last on October 23, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 23.2%
- Largest fall in the last year
- −21.95%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Uniphar: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Uniphar has been May: +12.39% on average, positive in 6 years out of 7. The weakest has been June: −6.84% on average, positive in 1 years out of 7. November, the current month, has been positive in 3 years out of 7 (+0.67% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.80% | +7.14% | 6 of 7 |
| February | −0.56% | −2.67% | 3 of 7 |
| March | −0.99% | −4.41% | 3 of 7 |
| April | +7.62% | +9.02% | 6 of 7 |
| May | +12.39% | +9.62% | 6 of 7 |
| June | −6.84% | −7.09% | 1 of 7 |
| July | +6.84% | +7.22% | 5 of 7 |
| August | +1.65% | +0.57% | 4 of 8 |
| September | −1.86% | −0.48% | 4 of 8 |
| October | −1.20% | −2.38% | 3 of 8 |
| November | +0.67% | −1.57% | 3 of 7 |
| December | +1.99% | −1.61% | 3 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Uniphar and its competitors
With revenue of EUR 3.1 billion in its latest fiscal year, Uniphar plc runs a healthcare services business spanning three divisions: Uniphar Medtech, Uniphar Pharma and Uniphar Supply Chain & Retail. Uniphar Medtech handles sales, marketing, servicing, quality and regulatory support for medical device makers, while Uniphar Pharma offers services across the life cycle of medicines, including access to products that are hard to source through conventional channels.
- Headquarters
- Dublin, Ireland
- Employees
- 3,500
- Founded
- 1967
- Chief executive
- Gerard Rabbette
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| UnipharUPR | $1.23B | 2.9% | 21.4 | −0.23% |
| NEUCANEU | $796.59M | 2.0% | 16.5 | −0.85% |
| Asker Healthcare GroupASKER | $2.84B | 6.7% | 37.8 | −6.65% |
| AmplifonAMP | $3.84B | 10.3% | 35.7 | +8.42% |
| GalenicaGALE | $5.42B | 4.8% | 28.2 | +11.17% |
| Sinopharm Group Ltd H1099 | $6.63B | 3.0% | 6.59 | −5.15% |
Same industry or related industries, similar size. Compare Uniphar with its competitors · Full profile
